PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Author's Avatar
Aug 12, 2022

PhaseBio+Pharmaceuticals%2C+Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities.